Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 4/20 | 0.98 |
| ▸ | HTR6 known ✓ | P50406 | 5/20 | 0.77 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.74 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.74 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.98 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548884 | 0.99 | HTR4 (1.00) | HTR4MEN1ALDH1A1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL678966 | 0.97 | HTR4 (0.96) | HTR4MEN1ALDH1A1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL7362378 | 0.95 | HTR4 (0.88) | HTR4MEN1ALDH1A1CYP2D6KMT2A | |
| SCHEMBL7358666 | 0.94 | HTR4 (0.90) | HTR4MEN1ALDH1A1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL7351744 | 0.91 | HTR4 (0.81) | HTR4MEN1ALDH1A1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL7360018 | 0.91 | HTR4 (0.81) | HTR4MEN1ALDH1A1CYP2D6KMT2A | |
| SCHEMBL7357278 | 0.90 | HTR4 (0.82) | HTR4MEN1ALDH1A1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL2946335 | 0.89 | MEN1 (0.98) | HTR4MEN1ALDH1A1CYP2D6KMT2A | |
| SCHEMBL2946020 | 0.88 | MEN1 (1.00) | HTR4MEN1ALDH1A1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL7357545 | 0.87 | HTR4 (0.76) | HTR4MEN1ALDH1A1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185263-A2 | RECEPTOR AGONISTS AND ANTAGONISTS | Respiratorius AB (SE) | 2002-03-13 | — | — | EP | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| US-9168250-B2 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2015-10-27 | — | — | US | disclosed |
| US-8859537-B2 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2014-10-14 | — | — | US | disclosed |
| US-20130274293-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | UNIVERSITÉ DE NÎMES (FR) | 2013-10-17 | — | — | US | disclosed |
| US-8436021-B2 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2013-05-07 | — | — | US | disclosed |
| EP-1556489-B1 | PHARMACEUTICAL COMPOSITION FOR PREPARING A MEDICINE FOR TREATING AND/OR PREVENTING A PATHOLOGY RELATED TO AN OBSESSIVE BEHAVIOUR OR OBESITY | CENTRE NAT RECH SCIENT (FR) | 2011-01-26 | — | — | EP | disclosed |
| US-20090124592-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | CENTRE NAT DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20060116341-A1 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, AN ORGANIZATION OF FRANCE (FR) | 2006-06-01 | — | — | US | disclosed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | disclosed |
| EP-1185263-A2 | RECEPTOR AGONISTS AND ANTAGONISTS | Respiratorius AB (SE) | 2002-03-13 | — | — | EP | disclosed |
| EP-1173168-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | Respiratorius AB (SE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000064441-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-11-02 | — | — | WO | disclosed |
| EP-0700383-B1 | NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS | SYNTEX INC (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5763458-A | NERVOUS SYSTEM DISORDERS, ANXIETY, ANTIDEPRESSANTS AND COGNITION ACTIVATORS | SYNTEX (U.S.A.) INC. (US) | 1998-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274293-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | OPRL1, HTR4, OPRM1 | HTR4 2/4885HTR6 21/4885HTR2A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.